About revolution medicines inc - RVMD
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
RVMD At a Glance
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, California 94063
| Phone | 1-650-481-6801 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Other | Net Income | -600,093,000.00 | |
| Sector | Health Technology | Employees | 534 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
RVMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.59 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.649 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.026 |
RVMD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,123,769.663 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RVMD Liquidity
| Current Ratio | 14.20 |
| Quick Ratio | 14.20 |
| Cash Ratio | 13.966 |
RVMD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -25.579 |
| Return on Equity | -29.334 |
| Return on Total Capital | -24.993 |
| Return on Invested Capital | -27.944 |
RVMD Capital Structure
| Total Debt to Total Equity | 5.997 |
| Total Debt to Total Capital | 5.658 |
| Total Debt to Total Assets | 5.218 |
| Long-Term Debt to Equity | 5.429 |
| Long-Term Debt to Total Capital | 5.122 |